Bringing a medical device from concept to commercialization is a marathon, not a sprint. At least that’s what Michael Chobotov, PhD, president and chief executive officer of TriVascular Technologies Inc., used to remind employees when the course they were running hit a steep incline. But, after the past two years Chobotov just experienced, he’s considering amending the cliché just a bit. "Maybe it’s a steeple chase." If so, TriVascular2 cleared a significant hurdle last month in securing $65 million and, more importantly, its freedom from Boston Scientific Corp.[See Deal]
TriVascular2—not to be confused with TriVascular Inc., the company Boston Scientific acquired in 2005—now is positioned to deliver what Hollywood...
